Loading…
5 companies · GEL, thousands · columns ordered by revenue
GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series
| Metric | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,002 | 8,847 | 23,889 | 14,988 | 11,743 | 9,527 | 5,817 | 2,462 |
| EBITDA | 1,150 | 945 | 2,409 | 510 | -85 | -477 | -1,190 | -209 |
| Net profit | -580 | 9,101 | 2,171 | 68 | -1,289 | -94 | -1,321 | -357 |
| Total assets | 20,063 | 32,172 | 23,337 | 24,616 | 21,498 | 4,530 | 4,886 | 4,255 |
| n (companies reporting) | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 2 |
GEL, thousands
| Company | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Pip Company | 0 | 1,452 | 1,575 | 1,810 | 2,112 | 2,309 | 3,003 | 1,276 |
| Med Parmasi Group | 0 | 1,824 | 1,645 | 2,094 | 2,610 | 2,282 | 1,474 | 1,185 |
| Sando Pharma | 0 | 4,272 | 4,761 | 5,363 | 5,621 | 4,936 | 1,341 | — |
| Medimex | 2,002 | 1,299 | — | — | — | — | — | — |
| Grasse Pharma Georgia | — | 0 | 15,908 | 5,721 | 1,400 | — | — | — |
Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.
Peer coverage varies by year — FY2017–FY2024 pool fewer than the 5 picked companies (see the n row). A year is never dropped because one peer is missing.
Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.